Pharmacophore model prediction, 3D-QSAR and molecular docking studies on vinyl sulfones targeting Nrf2-mediated gene transcription intended for anti-Parkinson drug design

Journal of Biomolecular Structure and Dynamics

Volumn 34, Issue 6, 2015, Pages 1282-1297

  Athar, Mohd ^a   Lone, Mohsinyousuf ^a   Khedkar, Vijay M ^b   Jha, Prakash Chandra ^a  

^a CENTRAL UNIVERSITY OF GUJARAT   (India)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

Nrf2; OH 1; Parkinson disease; Pharmacophore

Indexed keywords

ANTIPARKINSON AGENT; KELCH LIKE ECH ASSOCIATED PROTEIN 1; SULFONE DERIVATIVE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VINYL SULFONE DERIVATIVE; DIVINYL SULFONE; PROTEIN BINDING; SULFONE;

ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DISEASE COURSE; DRUG DESIGN; DRUG SCREENING; GENETIC TRANSCRIPTION; HYDROGEN BOND; MOLECULAR DOCKING; PARKINSON DISEASE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; BINDING SITE; CHEMISTRY; CONFORMATION; DRUG EFFECTS; METABOLISM; MOLECULAR DYNAMICS; MOLECULAR MODEL; REPRODUCIBILITY;

BINDING SITES; DRUG DESIGN; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS; SULFONES; TRANSCRIPTION, GENETIC;

EID: 84984991233     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2015.1077343     Document Type: Article

References (60)

1. Artursson, P., & Karlsson, J. (1991). Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochemical and Biophysical Research Communications, 175, 880-885. doi:10.1016/0006-291X(91)91647-U
2. Asraf Vazhapully, M., Vinod, D., & Zeinul Hukuman, N. H. (2014). Pharmacophore and 3D QSAR study of TGFβ inhibitors. Letters in Drug Design & Discovery, 11, 316-330. doi:10.2174/157018081131000071
3. Bahl, A., Joshi, P., Bharate, S., & Chopra, H. (2014). Pharmacophore modeling and 3D-QSAR studies of leucettines as potent Dyrk2 inhibitors. Medicinal Chemistry Research, 23, 1925-1933. doi:10.1007/s00044-013-0767-1
4. Beal, M. F. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson’s disease. Annals of the New York Academy of Sciences 991 120-131. doi:10.1111/j.1749-6632.2003.tb07470.x
5. Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., & Kalayci, O. (2012). Oxidative stress and antioxidant defense. World Allergy Organization Journal, 5, 9-19. doi:10.1097/WOX.0b013e3182439613
6. Choi, H. J., Lee, S. Y., Cho, Y., No, H., Kim, S. W., & Hwang, O. (2006). Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: Implications for Parkinson’s disease. Neurochemistry International, 48, 255-262. doi:10.1016/j.neuint.2005.10.011
7. Darvas, F., Keseru, G., Papp, A., Dorman, G., Urge, L., & Krajcsi, P. (2002). In silico and ex silico ADME approaches for drug discovery. Current Topics in Medicinal Chemistry, 2, 1287-1304. doi:10.2174/1568026023392841
8. de Lau, L. M., & Breteler, M. M. (2006). Epidemiology of Parkinson’s disease. The Lancet Neurology, 5, 525-535. doi:10.1016/S1474-4422(06)70471-9
9. de Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J., Drukarch, B., Hoozemans, J., & van Horssen, J. (2008). Nrf2-induced antioxidant protection: A promising target to counteract ROS-mediated damage in neurodegenerative disease? Free Radical Biology and Medicine, 45, 1375-1383. doi:10.1016/j.freeradbiomed.2008.09.001
10. Dhanik, A., McMurray, J. S., & Kavraki, L. (2011). On modeling peptidomimetics in complex with the SH2 domain of Stat3. Engineering in Medicine and Biology Society, EMBC, 2011 Annual International Conference of the IEEE (pp. 3229-3232). Boston, MA: IEEE.
11. Dixon, S., Smondyrev, A., Knoll, E., Rao, S., Shaw, D., & Friesner, R. (2006). PHASE: A new engine for pharma-cophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. Journal of Computer-Aided Molecular Design, 20, 647-671. doi:10.1007/s10822-006-9087-6
12. Duffy, E. M., & Jorgensen, W. L. (2000). Prediction of properties from simulations: Free energies of solvation in hexadecane, octanol, and water. Journal of the American Chemical Society, 122, 2878-2888. doi:10.1021/ja993663t
13. Fahn, S. (2008). The history of dopamine and levodopa in the treatment of Parkinson’s disease. Movement Disorders, 23, S497-S508. doi:10.1002/mds.22028
14. Fe, S. (2004). SMARTS, daylight chemical information systems. Retrieved from http://www.daylight.com/dayhtml/doc/theory/theory.smarts.html
15. Friesner, R. A., Murphy, R. B., Repasky, M. P., Frye, L. L., Greenwood, J. R., Halgren, T. A., Mainz, D. T. (2006). Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. Journal of Medicinal Chemistry, 49, 6177-6196. doi:10.1021/jm051256o
16. Geladi, P., & Kowalski, B. R. (1986). Partial least-squares regression: A tutorial. Analytica Chimica Acta, 185(0), 1-17. doi:10.1016/0003-2670(86)80028-9
17. Halgren, T. (2007). New method for fast and accurate binding-site identification and analysis. Chemical Biology & Drug Design, 69, 146-148. doi:10.1111/j.1747-0285.2007.00483.x
18. Halgren, T. A. (2009). Identifying and characterizing binding sites and assessing druggability. Journal of Chemical Information and Modeling, 49, 377-389. doi:10.1021/-ci800324 m
19. Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47, 1750-1759. doi:10.1021/ jm030644s
20. Hou, T., Wang, J., Li, Y., & Wang, W. (2011). Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized born surface area methods. II. The accuracy of ranking poses generated from docking. Journal of Computational Chemistry, 32, 866-877. doi:10.1002/jcc.21666
21. Hwang, O. (2013). Role of oxidative stress in Parkinson’s disease. Experimental Neurobiology, 22, 11-17. doi:10.5607/en.2013.22.1.11
22. Ioakimidis, L., Thoukydidis, L., Mirza, A., Naeem, S., & Reynisson, J. (2008). Benchmarking the reliability of QikProp. Correlation between experimental and predicted values. QSAR & Combinatorial Science, 27, 445-456.
23. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999). Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes & Development, 13, 76-86.
24. Johnson, J. A., Johnson, D. A., Kraft, A. D., Calkins, M. J., Jakel, R. J., Vargas, M. R., & Chen, P. C. (2008). The Nrf2-ARE pathway: An indicator and modulator of oxidative stress in neurodegeneration. Annals of the New York Academy of Sciences, 1147, 61-69. doi:10.1196/an-nals.1427.036
25. Jorgensen, W. L., Maxwell, D. S., & Tirado-Rives, J. (1996). Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. Journal of the American Chemical Society, 118, 11225-11236. doi:10.1021/ja9621760
26. Kennedy, T. (1997). Managing the drug discovery/development interface. Drug Discovery Today, 2, 436-444.
27. Kumar, S. P., Jha, P. C., Pandya, H. A., & Jasrai, Y. T. (2014). Implementation of pseudoreceptor-based pharmacophore queries in the prediction of probable protein targets: explorations in the protein structural profile of Zea mays. Molecular Biosystems, 10, 1833-1844. doi:10.1039/ c4mb00058 g
28. Kweon, M. H., Adhami, V. M., Lee, J. S., & Mukhtar, H. (2006). Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate. Journal of Biological Chemistry, 281, 33761-33772. doi:10.1074/jbc.M604748200
29. Li, J., Abel, R., Zhu, K., Cao, Y., Zhao, S., & Friesner, R. A. (2011). The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins: Structure, Function, and Bioinformatics, 79, 2794-2812. doi:10.1002/prot.23106
30. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46, 3-26. doi:10.1016/S0169-409X(00)00129-0
31. Lyne, P. D., Lamb, M. L., & Saeh, J. C. (2006). Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. Journal of Medicinal Chemistry, 49, 4805-4808. doi:10.1021/jm060522a
32. Ma, Q. (2013). Role of Nrf2 in oxidative stress and toxicity. Annual Review of Pharmacology and Toxicology, 53, 401-426. doi:10.1146/annurev-pharmtox-011112-140320
33. Mahapatra, M., Kumar, R., Malla, P., & Kumar, M. (2014). In silico accounting of novel pyridazine analogues as h-PTP 1B inhibitors: pharmacophore modelling, atom-based 3D QSAR and docking studies. Medicinal Chemistry Research, 23, 2701-2711. doi:10.1007/s00044-013-0797-8
34. Martin, Y. C. (2005). A bioavailability score. Journal of Medicinal Chemistry, 48, 3164-3170. doi:10.1021/jm0492002
35. Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005). Molecular pathophysiology of Parkinson’s disease. Annual Review of Neuroscience, 28, 57-87. doi:10.1146/an-nurev.neuro.28.061604.135718
36. Motohashi, H., & Yamamoto, M. (2004). Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends in Molecular Medicine, 10, 549-557.
37. OECD. (2007). Guidance document on validation of QSAR. (2007). Retrieved from http://www.oecd.org/chemicalsafety/risk-assessment/37849783zpdf
38. Ojha, P. K., Mitra, I., Das, R. N., & Roy, K. (2011). Further exploring rm2 metrics for validation of QSPR models. Chemometrics and Intelligent Laboratory Systems, 107, 194-205. doi:10.1016/j.chemolab.2011.03.011
39. Peterson, L. J., & Flood, P. M. (2012). Oxidative stress and microglial cells in Parkinson’s disease. Mediators of Inflammation, 2012, 1-12. 401264. doi:10.1155/2012/401264
40. Prakash Tanwar, O., Karthikeyan, C., Hari Narayana Moorthy, N. S., & Trivedi, P. (2010). 3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors. Medicinal Chemistry, 6, 277-285. doi:10.2174/1573406107 93358846
41. Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., & Hamilton, R. L. (2007). Expression of Nrf2 in neurodegenerative diseases. Journal of Neuropathology and Experimental Neurology, 66, 75-85. doi:10.1097/nen.0b013e31802d6da9
42. Roy, K., & Kar, S. (2014). The rm2 metrics and regression through origin approach: Reliable and useful validation tools for predictive QSAR models (Commentary on ‘is regression through origin useful in external validation of QSAR models?’). European Journal of Pharmaceutical Sciences, 62, 111-114. doi:10.1016/j.ejps.2014.05.019
43. Roy, K., Kar, S., & Ambure, P. (2015). On a simple approach for determining applicability domain of QSAR models. Chemometrics and Intelligent Laboratory Systems, 145, 22-29. doi:10.1016/j.chemolab.2015.04.013
44. Roy, K., Mitra, I., Kar, S., Ojha, P. K., Das, R. N., & Kabir, H. (2012). Comparative studies on some metrics for external validation of QSPR models. Journal of Chemical Information and Modeling, 52, 396-408. doi:10.1021/ci200520 g
45. Savitt, J. M., Dawson, V. L., & Dawson, T. M. (2006). Diagnosis and treatment of Parkinson disease: Molecules to medicine. Journal of Clinical Investigation, 116, 1744-1754. doi:10.1172/JCI29178
46. Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., & Sherman, W. (2010). Prediction of absolute salvation free energies using molecular dynamics free energy perturbation and the OPLS force field. Journal of Chemical Theory and Computation, 6, 1509-1519.
47. Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011). Parkinson’s disease: Genetics and pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 6, 193-222. doi:10.1146/annurev-pathol-011110-130242
48. Sporn, M. B., & Liby, K. T. (2012). NRF2 and cancer: The good, the bad and the importance of context. Nature Reviews Cancer, 12, 564-571.
49. Teli, M., & Rajanikant, G. K. (2012). Pharmacophore generation and atom-based 3D-QSAR of N-iso-propyl pyrrole-based derivatives as HMG-CoA reductase inhibitors. Organic and Medicinal Chemistry Letters, 2(1), 1-10. doi:10.1186/2191-2858-2-25
50. Testa, C. M., Sherer, T. B., & Greenamyre, J. T. (2005). Rotenone induces oxidative stress and dopaminergic neuron Pharmacophore model prediction 1297 damage in organotypic substantia nigra cultures. Molecular Brain Research, 134, 109-118. doi:10.1016/j.molbrainres.2004.11.007
51. Uttara, B., Singh, A. V., Zamboni, P., & Mahajan, R. T. (2009). Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology, 7, 65-74. doi:10.2174/157015909787602823
52. van de Waterbeemd, H., & Gifford, E. (2003). ADMET in silico modelling: Towards prediction paradise? Nature Reviews Drug Discovery, 2, 192-204. doi:10.1038/nrd1032
53. Verma, J., Khedkar, V. M., & Coutinho, E. C. (2010). 3D-QSAR in drug design - A review. Current Topics in Medicinal Chemistry, 10, 95-115. doi:10.2174/ 156802610790232260
54. Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., & Talalay, P. (2004). Protection against electrophile and oxidant stress by induction of the phase 2 response: Fate of cysteines of the Keap1 sensor modified by inducers. Proceedings of the National Academy of Sciences, 101, 2040-2045. doi:10.1073/pnas.0307301101
55. Willett, P., Barnard, J. M., & Downs, G. M. (1998). Chemical similarity searching. Journal of Chemical Information and Computer Sciences, 38, 983-996. doi:10.1021/ci9800211
56. Wolber, G., Seidel, T., Bendix, F., & Langer, T. (2008). Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discovery Today, 13, 23-29. doi:10.1016/j.drudis.2007.09.007
57. Woo, S. Y., Kim, J. H., Moon, M. K., Han, S. H., Yeon, S. K., Choi, J. W., & Park, K. D. (2014). Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson’s disease therapy. Journal of Medicinal Chemistry, 57, 1473-1487. doi:10.1021/jm401788m
58. Yu, Z., Jacobson, M. P., & Friesner, R. A. (2006). What role do surfaces play in GB models? A new-generation of surface-generalized born model based on a novel gaussian surface for biomolecules. Journal of Computational Chemistry, 27, 72-89. doi:10.1002/jcc.20307
59. Zhang, Y., Dawson, V. L., & Dawson, T. M. (2000). Oxidative stress and genetics in the pathogenesis of Parkinson’s disease. Neurobiology of Disease, 7, 240-250. doi:10.1006/nbdi.2000.0319
60. Zhang, J., Liu, G., & Tang, Y. (2009). Chemical function-based pharmacophore generation of selective κ-opioid receptor agonists by catalyst and phase. Journal of Molecular Modeling, 15, 1027-1041.